Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia
T. Stroup,L. Jarskog
DOI: https://doi.org/10.1136/ebmh.13.2.53
2010-05-01
Evidence-Based Mental Health
Abstract:ED FROM Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006627. Correspondence to: Katja Komossa, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische UniversitätMünchen Klinikum rechts der Isar, Moehlstrasse 26, München, 81675, Germany; k.komossa@lrz.tu-muenchen.de Sources of funding: Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern, Germany. Bundesministerium für Bildung und Forschung, Germany. OM M EN TA RY This report by Komassa and colleagues systematically reviews randomised, controlled trials that compared ziprasidone to ‘other atypical’ antipsychotics. Although the authors appropriately question the validity of the atypical category, they limit the scope of the review by using this criterion to select studies. With many antipsychotics available, clinicians need to know whether a drug has important distinguishing features. The main results of this review suggest that indeed ziprasidone has characteristics that clinicians need to consider. Ziprasidone's side-effect profi le is its most robust distinction from other atypical antipsychotics however, differences in effi cacy have also been identifi ed. For example, ziprasidone causes less weight gain and cholesterol increase than olanzapine, quetiapine and risperidone, whereas its effi cacy is slightly less than that of amisulpride, olanzapine and risperidone. On the basis of this review, it is possible to conclude that the appropriate patients for a ziprasidone trial are those who are expected to respond well to antipsychotic treatment and for whom there is little reason to risk using drugs with a higher risk of metabolic problems. For example, ziprasidone might be a good choice for patients experiencing a fi rst episode of psychosis, or for someone who responded well to another antipsychotic but gained considerable weight. If it does not work well in these situations, then a more effi cacious drug can be tried. However, if symptom control is the dominant issue, then it might be prudent to begin with one of the more effi cacious drugs. A shortcoming of this review is that it does not include comparisons between ziprasidone and other key antipsychotics also associated with relatively benign effects on metabolic parameters (eg, aripiprazole and perphenazine). The available evidence does not suggest that ziprasidone has meaningful advantages over these drugs.1 2 T Scott Stroup, L Fredrik Jarskog New York State Psychiatric Institute, Columbia University, College of Physicians and Surgeons, New York, USA. Competing interests: TSS has been paid for consulting for AstraZeneca, Eli Lilly, Janssen and Pfi zer. LFJ has received research grants from Glaxo SmithKline, Novartis and AstraZeneca. 1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23. 2. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363–70. 15_ebmental1042.indd 53 5/11/2010 1:07:35 PM